GB2599912B - New formulation - Google Patents

New formulation Download PDF

Info

Publication number
GB2599912B
GB2599912B GB2016229.3A GB202016229A GB2599912B GB 2599912 B GB2599912 B GB 2599912B GB 202016229 A GB202016229 A GB 202016229A GB 2599912 B GB2599912 B GB 2599912B
Authority
GB
United Kingdom
Prior art keywords
new formulation
formulation
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2016229.3A
Other versions
GB202016229D0 (en
GB2599912A (en
Inventor
Gallagher Jasmina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diomed Developments Ltd
Original Assignee
Diomed Developments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diomed Developments Ltd filed Critical Diomed Developments Ltd
Priority to GB2016229.3A priority Critical patent/GB2599912B/en
Publication of GB202016229D0 publication Critical patent/GB202016229D0/en
Priority to PCT/EP2021/077016 priority patent/WO2022078772A1/en
Priority to EP21790391.3A priority patent/EP4228641A1/en
Priority to US18/031,296 priority patent/US20230372324A1/en
Publication of GB2599912A publication Critical patent/GB2599912A/en
Application granted granted Critical
Publication of GB2599912B publication Critical patent/GB2599912B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB2016229.3A 2020-10-13 2020-10-13 New formulation Active GB2599912B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB2016229.3A GB2599912B (en) 2020-10-13 2020-10-13 New formulation
PCT/EP2021/077016 WO2022078772A1 (en) 2020-10-13 2021-09-30 Gel formulations comprising montelukast
EP21790391.3A EP4228641A1 (en) 2020-10-13 2021-09-30 Gel formulations comprising montelukast
US18/031,296 US20230372324A1 (en) 2020-10-13 2021-09-30 Gel formulations comprising montelukast

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2016229.3A GB2599912B (en) 2020-10-13 2020-10-13 New formulation

Publications (3)

Publication Number Publication Date
GB202016229D0 GB202016229D0 (en) 2020-11-25
GB2599912A GB2599912A (en) 2022-04-20
GB2599912B true GB2599912B (en) 2023-04-19

Family

ID=73460378

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2016229.3A Active GB2599912B (en) 2020-10-13 2020-10-13 New formulation

Country Status (1)

Country Link
GB (1) GB2599912B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105803A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2010104281A2 (en) * 2009-03-11 2010-09-16 주식회사 엘지생명과학 Composition for improving atopic skin diseases
WO2020109230A1 (en) * 2018-11-26 2020-06-04 Mmc Intellectual Property Institute, S.L. Montelukast for the treatment of erosive hand osteoarthritis
WO2020143744A1 (en) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. New formulations containing leukotriene receptor antagonists
US20200237651A1 (en) * 2016-05-04 2020-07-30 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105803A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2010104281A2 (en) * 2009-03-11 2010-09-16 주식회사 엘지생명과학 Composition for improving atopic skin diseases
US20200237651A1 (en) * 2016-05-04 2020-07-30 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
WO2020109230A1 (en) * 2018-11-26 2020-06-04 Mmc Intellectual Property Institute, S.L. Montelukast for the treatment of erosive hand osteoarthritis
WO2020143744A1 (en) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. New formulations containing leukotriene receptor antagonists

Also Published As

Publication number Publication date
GB202016229D0 (en) 2020-11-25
GB2599912A (en) 2022-04-20

Similar Documents

Publication Publication Date Title
IL284688A (en) Formulation
GB202007546D0 (en) Formulation
GB201913232D0 (en) Aerosolisable formulation
GB2599912B (en) New formulation
GB202115303D0 (en) New formulation
GB202108181D0 (en) New formulation
GB2595300B (en) Novel Formulation
GB2595453B (en) Novel Formulation
IL307849A (en) Sotorasib formulation
IL308046A (en) Alpelisib formulation
GB202108165D0 (en) Formulation
GB202107439D0 (en) Formulation
GB202107203D0 (en) Formulation
GB202103970D0 (en) Formulation
GB202102636D0 (en) Formulation
GB202102408D0 (en) Formulation
GB202016274D0 (en) Formulation
GB202010573D0 (en) Formulation
GB202006008D0 (en) Aerosolisable formulation
GB202005340D0 (en) Formulation
GB202003048D0 (en) Formulation
IL305977A (en) Formulation comprising ceralasertib
GB202007620D0 (en) Novel formulation
GB2587402B (en) Formulation
GB202312814D0 (en) Formulation